Rujianing (Lerociclib) – Breast Cancer | HongKong DengYue Medicine
- Generic Name/Brand Name: Lerociclib / Rujianing®
- Indications: Breast Cancer
- Dosage Form: Tablet
- Specification: 50 mg × 42 tablets
Lerociclib Application Scope
It is an oral, selective CDK4/6 inhibitor approved for the treatment of HR+/HER2- advanced or metastatic breast cancer in adults. It can be combined with:
-
Aromatase inhibitors as first-line endocrine therapy
-
Fulvestrant for patients progressing after prior endocrine therapy
It is designed for continuous oral administration, providing sustained target inhibition with a favorable safety profile, including reduced risk of severe neutropenia and diarrhea compared to other CDK4/6 inhibitors.

Lerociclib Characteristics
-
Ingredients: Lerociclib Hydrochloride (active ingredient)
-
Properties: Oral film-coated tablet
-
Packaging Specification: 50 mg × 42 tablets/box
-
Storage: Store in a cool, dry place below 25°C, protect from light and moisture
-
Expiry Date: As per manufacturer
-
Executive Standard: NMPA-approved standard for oral oncology drugs
-
Approval Number: NMPA Class 1 Innovative Drug (Approved: 2025/05/29)
-
Date of Revision: 2025-05-29
-
Manufacturer: Jiahe Biopharma (Cayman) Holdings Ltd.
Guidelines for the Use of Rujianing
-
Dosage and Administration:
-
Recommended Dose: 50 mg orally, once daily (as per physician’s guidance)
-
Administration: Continuous oral dosing
-
Missed Dose: Take as soon as remembered; do not double-dose dose
-
-
Adverse Reactions:
-
Common Adverse Reactions: Neutropenia, fatigue, nausea
-
Serious Adverse Reactions: Severe neutropenia, thrombocytopenia
-
-
Contraindications:
-
Hypersensitivity to Lerociclib or excipients
-
Severe hepatic impairment
-
-
Precautions:
-
Monitor blood counts regularly.
-
Adjust dose in case of hematologic toxicity.
-
Lerociclib Interactions
-
Concomitant strong CYP3A4 inhibitors or inducers may alter plasma levels.
-
Avoid live vaccines during treatment.
-
Use caution with other myelosuppressive agents.
Note:
- If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
- This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.










Reviews
There are no reviews yet.